Category: Federal Forum Posters
Purpose: The combination of piperacillin/tazobactam and vancomycin is used frequently as empiric therapy and to treat complicated infections. Recent studies have shown that there may be an increased risk of acute kidney injury (AKI) when vancomycin and piperacillin/tazobactam are used together compared with vancomycin alone. The objective of this study is to see if there is a difference in the rate of AKI in veterans receiving piperacillin/tazobactam and vancomycin compared to veterans receiving meropenem and vancomycin, and vancomycin alone.
Methods: This study will be submitted to the Institutional Review Board for approval. The information technology department will identify subjects meeting the general inclusion and exclusion criteria using a retrospective database search. A sample of 100 veterans admitted to SAVAHCS, both ICU and non-ICU, who received either piperacillin/tazobactam and vancomycin, meropenem and vancomycin, or vancomycin monotherapy for greater than or equal to 48 hours between 9/1/2014 and 9/1/2018, who were between the ages of 18 and 89 years old, with baseline and daily serum creatinine measurements, and not on hemodialysis will be included in the study. Data on demographics, comorbidities that influence renal function, concomitant nephrotoxic drugs, sites of infections, the length of time study drugs were administered, and the time to acute kidney injury will be collected by chart review. AKI will be defined as an increase in serum creatinine greater than 0.5mg/dL, or greater than 50% from baseline after 48 hours of therapy. The incidence of AKI in each group will be compared to see if there is a significant difference between them.
Results: not applicable
Conclusion: not applicable
Marshall Renna– PGY1 Resident, Souther Arizona VA Health Care System, Tucson, AZ